Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial-Reference-Cited by-同舟云学术

Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: the study protocol of J-SUPPORT 1602 (TOPICS study), a randomized double-blinded phase 3 trial

Published:2018-09-06 Issue:1 Volume:18 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Zenda Sadamoto,Yamaguchi Takuhiro,Yokota Tomoya,Miyaji Tempei,Mashiko Tomoe,Tanaka Mari,Yonemura Masahito,Takeno Misaki,Okano Tomoka,Kawasaki Toshikatsu,Nakamori Yuko,Ishii Shinobu,Shimada Sanae,Kanamaru Miyuki,Uchitomi Yosuke

Funder

Japan Agency for The National Cancer Center Research and Development Fund

Project Mirai Cancer Research Grants

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-018-4763-1.pdf

Reference17 articles.

1. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22):2091–8.

2. Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–8.